Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,831.80 | 37.40 | 0.43% |
| CAC 40 | 7,835.31 | 129.20 | -1.62% |
| DAX 40 | 24,939.35 | 259.84 | -1.03% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,428.27 | 177.73 | -1.68% |
| HKSE | 23,969.30 | 643.97 | -2.62% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,326.72 | 630.00 | -0.91% |
| NZX 50 Index | 13,664.70 | 145.81 | -1.06% |
| S&P 500 | 7,666.45 | 14.91 | 0.19% |
| S&P/ASX 200 | 8,656.70 | 42.30 | 0.49% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |